Edition:
United States

People: ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

3.20USD
16 Nov 2018
Change (% chg)

$0.12 (+3.90%)
Prev Close
$3.08
Open
$3.08
Day's High
$3.23
Day's Low
$2.91
Volume
847,433
Avg. Vol
263,821
52-wk High
$5.24
52-wk Low
$1.91

Cooper, Laurence 

Dr. Laurence James Neil Cooper, M.D., Ph.D., is President, Chief Executive Officer, Director of the Company. Prior to joining us, Dr. Cooper led the Pediatric Cell Therapy service (formally named the BMT program) as a tenured professor at the University of Texas M.D. Anderson Cancer Center, or MD Anderson, where he had worked since 2006. In addition to caring for children, adolescents and young adults undergoing autologous and allogeneic hematopoietic stem-cell transplantation, referred to as HSCT, at MD Anderson, he ran a laboratory translating immunology into clinical practice. His program had multiple investigator-initiated trials that infuse T cells and NK cells to target malignancies. Dr. Cooper also holds an appointment as a Visiting Scientist at MD Anderson and as Adjunct Professor of Pathology & Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Cooper obtained his BA at Kenyon College in Gambier, Ohio and M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland before training in Pediatric Oncology and Bone Marrow Transplantation, or BMT, at the Fred Hutchinson cancer Research Center in Seattle.

Basic Compensation

Total Annual Compensation, USD 1,375,000
Restricted Stock Awards, USD 1,140,720
Long-Term Incentive Plans, USD --
All Other, USD 78,524
Fiscal Year Total, USD 2,594,240

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Laurence Cooper

2,594,240

Kevin Lafond

581,224

David Mauney

2,297,970

Lynn Ferrucci

--

Scott Tarriff

128,178

James Cannon

129,448
As Of  30 Dec 2017